Table 2.
EBV DNA copy number in plasma and PBMCs by disease group
| Diagnosis | # of patients with sufficient plasma for assay | N (% of patients with EBV DNA in plasma) | Median plasma copies/mL (range) | Compared with patients with no EBV disease (n = 2014)* | # of patients with sufficient PBMCs for assay | N (% of patients with EBV DNA in PBMCs) | Median PBMC copies / 100 000 lymphocytes (range) | Compared with patients with no EBV disease (n = 1395)* |
|---|---|---|---|---|---|---|---|---|
| Active and untreated, systemic EBV+ diseases | 105 | 104 (99) | 14 783 (0-7.3 × 107) | P < .0001 | 70 | 57 (81) | 1456 (0-1.5 × 106) | P < .0001 |
| IM | 20 | 19 (95) | 6273 (0-250 000) | P < .0001 | 17 | 15 (88) | 1793 (0-32 710) | P < .0001 |
| EBV+ HLH | 7 | 7 (100) | 295 720 (6054-7.3 × 107) | P < .001 | 3 | 2 (67) | 5998 (0-1.4 × 106) | — |
| Biopsy-proven EBV+ PTLD | 12 | 12 (100) | 54 960 (170-961 520) | P < .0001 | 7 | 7 (100) | 2842 (437-64 213) | P < .0001 |
| Empiric treatment of unproven EBV+ PTLD | 17 | 17 (100) | 4300 (460-471 100) | P < .0001 | 10 | 9 (90) | 10 085 (0-1.5 × 106) | P < .0001 |
| NPC | 5 | 5 (100) | 1690 (447-32 870) | P < .0001 | 4 | 0 (0) | 0 (0-0) | — |
| NHL | 24 | 24 (100) | 21 881 (372-4.7 × 106) | P < .0001 | 14 | 12 (86) | 239 (0-39 225) | P < .0001 |
| HIV-associated DLBCL | 7 | 7 (100) | 6300 (1290-1.4 × 106) | P < .001 | 3 | 3 (100) | 11 158 (170-39 225) | — |
| HIV plasmablastic lymphoma | 2 | 2 (100) | 7578 (3176-11 980) | — | 1 | 1 (100) | 28 072 | — |
| Peripheral T-cell lymphoma | 8 | 8 (100) | 47 445 (372-1.5 × 106) | P < .001 | 4 | 4 (100) | 14 355 (165-32 338) | — |
| ENKTL | 3 | 3 (100) | 935 764 (46 000-1.5 × 106) | — | 1 | 1 (100) | 32 338 | — |
| Peripheral T-cell lymphoma, other | 5 | 5 (100) | 5030 (372-125 988) | P < .01 | 3 | 3 (100) | 252 (165-28 458) | — |
| Immunodeficiency-associated DLBCL | 1 | 1 (100) | 70 277 | — | 1 | 0 (0) | 0 | — |
| Lymphomatoid granulomatosis | 4 | 4 (100) | 188 056 (2179-4.6 × 106) | — | 3 | 2 (67) | 221 (0-571) | — |
| Burkitt lymphoma | 2 | 2 (100) | 127 000 (1000-253 000) | — | 2 | 2 (100) | 108 (86-130) | — |
| HL | 12 | 12 (100) | 51 418 (2410-709 804) | P < .0001 | 11 | 9 (82) | 1328 (0-6319) | P < .0001 |
| HIV-associated | 9 | 9 (100) | 20 176 (2410-709 804) | P < .0001 | 8 | 7 (88) | 1498 (0-6319) | P < .0001 |
| Lymphoproliferative disorder | 7 | 7 (100) | 2076 (191-117 109) | P < .01 | 3 | 2 (67) | 86 (0-239) | — |
| Oral hairy leukoplakia | 1 | 1 (100) | 9901 | — | 1 | 1 (100) | 1517 | — |
| Partially-treated EBV+ disease | 5 | 4 (80) | 378 (0-805) | P ≤ .05 | 4 | 3 (75) | 192 (0-450) | — |
| EBV+ disease in remission | 26 | 5 (19) | 0 (0-980) | NS | 20 | 16 (80) | 126 (0-6053) | P < .0001 |
| EBV+ CNS disease | 6 | 2 (33) | 0 (0-1958) | NS | 6 | 4 (67) | 426 (0-2279) | P < .05 |
| Primary CNS lymphoma | 3 | 0 (0) | 0 (0-0) | — | 3 | 3 (100) | 700 (151-1549) | — |
| EBV encephalitis | 3 | 2 (67) | 1802 (1645-1958) | — | 3 | 1 (33) | 2279 | — |
DLBCL, diffuse large B-cell lymphoma; NS, not significant.
*
Comparison by Kruskal–Wallis test, with Dunn’s correction for multiple comparisons.